Pumitamig and Elfetabart Drozuntecan Show Early Promise in Small Cell Lung Cancer Trial
Source Summary
An investigational combination of pumitamig and elfetabart drozuntecan demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer, according to Phase Ib/II trial data presented at the 2026 IASLC World Conference on Lung Cancer. The BNT324-01 trial is ongoing.
Why it matters
Early-stage clinical data on a new drug combination for small cell lung cancer, a difficult-to-treat malignancy, may inform future treatment options for patients with this disease.
